Humanigen Inc. [NASDAQ: HGEN] stock went on a downward path that fall over -32.00% on Monday, amounting to a one-week price decrease of less than -25.93%. The company report on November 6, 2020 that Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19.
The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) in support of Operation Warp Speed (OWS) aims to improve the availability of lenzilumab for patients with COVID-19.
Humanigen’s development efforts complemented by full-scale, integrated team of OWS leading experts and U.S. Government decision makers dedicated to advancing lenzilumab ahead of a potential Emergency Use Authorization (EUA) submission .
Over the last 12 months, HGEN stock rose by 127.71%. The average equity rating for HGEN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $391.33 million, with 30.68 million shares outstanding and 30.60 million shares in the current float. Compared to the average trading volume of 521.60K shares, HGEN stock reached a trading volume of 3150731 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Humanigen Inc. [HGEN]:
Cantor Fitzgerald have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 21, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on October 14, 2020, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another raise to $25, while ROTH Capital analysts kept a Buy rating on HGEN stock.
The Average True Range (ATR) for Humanigen Inc. is set at 1.53 The Price to Book ratio for the last quarter was 7.74, with the Price to Cash per share for the same quarter was set at 0.85.
HGEN Stock Performance Analysis:
Humanigen Inc. [HGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.93. With this latest performance, HGEN shares dropped by -34.94% in over the last four-week period, additionally plugging by 87.53% over the last 6 months – not to mention a rise of 127.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 34.28, with the RSI for the last a single of trading hit 27.07, and the three-weeks RSI is set at 37.44 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 11.42, while it was recorded at 10.61 for the last single week of trading, and 10.95 for the last 200 days.
Insight into Humanigen Inc. Fundamentals:
Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.90 and a Current Ratio set at 3.90.
Humanigen Inc. [HGEN] Insider Position Details
There are presently around $12 million, or 20.10% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: FIRST LIGHT ASSET MANAGEMENT, LLC with ownership of 804,598, which is approximately New of the company’s market cap and around 40.46% of the total institutional ownership; BLACKROCK INC., holding 700,940 shares of the stock with an approximate value of $5.59 million in HGEN stocks shares; and IEQ CAPITAL, LLC, currently with $0.17 million in HGEN stock with ownership of nearly New of the company’s market capitalization.
4 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 1,527,585 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 1,527,585 shares, according to the latest SEC report filing. HGEN stock had 4 new institutional investments in for a total of 1,527,585 shares, while 0 institutional investors sold positions of 0 shares during the same period.